FDA Generics Office Sets Aspirational Goal To Clear Unmeasured ANDAs
This article was originally published in The Pink Sheet Daily
Office of Generic Drugs restructures again and adds specialist who helped relieve supplement backlog to improve ANDA review process.
You may also be interested in...
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.